These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34157091)

  • 21. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.
    Liang Y; Tebaldi T; Rejeski K; Joshi P; Stefani G; Taylor A; Song Y; Vasic R; Maziarz J; Balasubramanian K; Ardasheva A; Ding A; Quattrone A; Halene S
    Leukemia; 2018 Dec; 32(12):2659-2671. PubMed ID: 29858584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.
    Yoshimi A; Abdel-Wahab O
    Clin Cancer Res; 2017 Jan; 23(2):336-341. PubMed ID: 27836865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. U2AF1 mutations alter splice site recognition in hematological malignancies.
    Ilagan JO; Ramakrishnan A; Hayes B; Murphy ME; Zebari AS; Bradley P; Bradley RK
    Genome Res; 2015 Jan; 25(1):14-26. PubMed ID: 25267526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.
    Hahn CN; Venugopal P; Scott HS; Hiwase DK
    Immunol Rev; 2015 Jan; 263(1):257-78. PubMed ID: 25510282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Targeting of RNA Splicing in Cancer.
    Bonner EA; Lee SC
    Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.
    Yoshimi A; Abdel-Wahab O
    Int J Hematol; 2017 Jun; 105(6):720-731. PubMed ID: 28466384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SF3B1 mutant myelodysplastic syndrome: Recent advances.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic targeting of splicing in cancer.
    Lee SC; Abdel-Wahab O
    Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of microRNAs in normal and malignant hematopoiesis.
    Vasilatou D; Papageorgiou S; Pappa V; Papageorgiou E; Dervenoulas J
    Eur J Haematol; 2010 Jan; 84(1):1-16. PubMed ID: 19744129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Representative cancer-associated U2AF2 mutations alter RNA interactions and splicing.
    Maji D; Glasser E; Henderson S; Galardi J; Pulvino MJ; Jenkins JL; Kielkopf CL
    J Biol Chem; 2020 Dec; 295(50):17148-17157. PubMed ID: 33020180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
    Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
    Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer-Related Mutations Alter RNA-Driven Functional Cross-Talk Underlying Premature-Messenger RNA Recognition by Splicing Factor SF3b.
    Spinello A; Janos P; Rozza R; Magistrato A
    J Phys Chem Lett; 2023 Jul; 14(27):6263-6269. PubMed ID: 37399065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetics of hematopoiesis and hematological malignancies.
    Hu D; Shilatifard A
    Genes Dev; 2016 Sep; 30(18):2021-2041. PubMed ID: 27798847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative levels of alternative transcripts of the ING1 gene and lack of mutations of p33/ING1 in haematological malignancies.
    Bromidge T; Lynas C
    Leuk Res; 2002 Jul; 26(7):631-5. PubMed ID: 12008079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
    Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
    Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
    Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
    Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic approaches targeting splicing factor mutations in myelodysplastic syndromes and acute myeloid leukemia.
    Figg JW; Barajas JM; Obeng EA
    Curr Opin Hematol; 2021 Mar; 28(2):73-79. PubMed ID: 33492002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The molecular basis of myeloid malignancies.
    Kitamura T; Inoue D; Okochi-Watanabe N; Kato N; Komeno Y; Lu Y; Enomoto Y; Doki N; Uchida T; Kagiyama Y; Togami K; Kawabata KC; Nagase R; Horikawa S; Hayashi Y; Saika M; Fukuyama T; Izawa K; Oki T; Nakahara F; Kitaura J
    Proc Jpn Acad Ser B Phys Biol Sci; 2014; 90(10):389-404. PubMed ID: 25504228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clonal hematopoiesis: Molecular basis and clinical relevance.
    Kunimoto H; Nakajima H
    Leuk Res; 2020 Nov; 98():106457. PubMed ID: 33010619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.